Back To: Home : Featured Technology : Stem Cell
CLICK HERE FOR WHAT'S NEW IN:
 

Sigma-Aldrich to offer Stemgent’s lentivirus-based gene delivery products for regenerative medicine, stem cell research
December 2009
SHARING OPTIONS:

ST. LOUIS—Sigma-Aldrich announced Nov. 10 that it entered into an exclusive worldwide distribution agreement with Stemgent Inc. to offer Stemgent's portfolio of lentivirus-based delivery systems for the generation of induced pluripotent stem (iPS) cells. The reprogramming technologies offered under the terms of the agreement involve proprietary viral vectors from Stemgent, lentivirus technology from Sigma-Aldrich and Dox Inducible expression from TET Systems. These technologies have been fully validated in Stemgent's laboratories and are expected to allow researchers to efficiently reprogram mouse and human cells into iPS cells, enabling researchers to investigate and address the challenges facing the field of regenerative medicine. Financial details of the agreement were not disclosed.

Back


PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.